KOL Identification

A multi-billion dollar life science company needed pre diligence on a potential acquisition target

A leading private equity firm and management team sought out DeciBio as a strategic partner to advise on the life sciences market and perform due-diligences in support of the development of a novel life sciences tools platform

A diagnostics company requested DeciBio to help an advisory board (ad board) to understand how to position its relatively new somatic oncology genomics profiling product in an already competitive market

A top-10 diagnostics company wanted to gauge preparedness and reactions to implementation of IVDR, and how that would impact a potential new product

The ventures arm of a top-20 U.S. health system sought support developing a go-to-market strategy for RWD-augmented biobank offerings

A large multi-national diagnostic company was interested in understanding the market landscape and potential strategy for the decentralization of NIPT in the U.S.